FTC issues policy condemning the improper listing of patents in FDA's Orange Book

Zachary Brennan

Senior Editor

The Federal Trade Commission voted 3-0 on Thursday to issue a policy statement to increase scrutiny of improper listing of patents in the FDA’s Orange …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FTC issues policy condemning the improper listing of patents in FDA's Orange Book

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

How Keymed steered the China-to-US NewCo model in biotech

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Drug packaging manufacturers brace for impact as EU chemical ban looms

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FTC is­sues pol­i­cy con­demn­ing the im­prop­er list­ing of patents in FDA's Or­ange Book

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FTC issues policy condemning the improper listing of patents in FDA's Orange Book